HealthQuill Austria
Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations of the US-based company’s peptides for an upfront payment of $493 million.
Drugs Health Medical

Austria’s Cyprumed in $493 million pact with Merck to develop peptides

HQ Team April 17, 2025: Austria’s Cyprumed GmbH has announced a license and option agreement with Merck & Co., to develop oral formulations.

Read More
The EU faces a new set of healthcare challenges potentially more potent than the Covid-19 pandemic, and some states are “miles away” from ensuring efficient preventive environments, according to a report from the independent Globsec.
Drugs Health Pharma

EU faces new healthcare threats, some states ‘miles away’ from ready 

The EU faces a new set of healthcare challenges potentially more potent than the Covid-19 pandemic, and some states are “miles away” from.

Read More